The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...

Major companies like pharma giant GlaxoSmithKline (GSK) have established their largest AI teams in London. The city is a global leader in AI talent, as well as home to leading AI research centres, ...

GlaxoSmithKline is investing in artificial ... clients in one quarter of the time normally needed. Exscientia and GSK aim to discover novel and selective small molecules for up to 10 disease ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...